A pharmaceutical composition in form of an aqueous colloid or an aqueous suspension of particles up to a size of 100 μm comprises or consists of amphiphilic sulfonate or sulfate of a hydrophilic cancer drug having a solubility in water or aqueous body fluid of less than 0.1 % by weight. Also disclosed are the particles in powderous form, methods for their production and for the production of the colloid and the courser suspension, a method of treating liver cancer, in particular solid liver cancer tumours, by administration of the pharmaceutical composition, and a method of designing a composition according to the invention.

A pharmaceutical composition comprises: a plurality of first particulates comprising a 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, preferably a triptan selected from sumatriptan, almotriptan, frovatriptan, eletriptan, rizatriptan or naratriptan; and a plurality of second particulates comprising an antiemetic or a pharmaceutically acceptable salt thereof, preferably promethazine, characterised in that the weight of the plurality of first particulates to the plurality of second particulates is from about 3:1 to about 5:1 respectively. Preferably the plurality of first particulates comprises about 50-150mg of the 5HT1B receptor agonist or pharmaceutically acceptable salt thereof; about 1-10mg of polyvinylpyrrolidone; about 50-100mg microcrystalline cellulose; about 1-10mg croscarmellose sodium; about 0.1-5mg of magnesium stearate; and a coating material; and the plurality of second particulates comprises: about 10-50mg antiemetic or a pharmaceutically acceptable salt thereof; about 10-50mg microcrystalline cellulose; about 0.1-5mg of croscarmellose sodium and a coating material. Preferably the coating material is polyvinyl alcohol. The composition is useful in the treatment of headache, headache-associated symptoms such as nausea or vomiting, or adverse effects associated with triptan administration.

Branched polyesters carrying dendrons are a useful class of nanomaterials which exhibit good handling properties and stability, can degrade to a high extent, and are effective encapsulation materials. They can be used to make nanoprecipitated particles which may for example be used in therapy. Furthermore, these materials can be synthesised by economical and tailorable processes. The materials can be prepared by the ring-opening polymerisation (ROP) of monofunctional lactone monomers and difunctional lactone monomers, using dendron initiators.

The invention relates generally to compositions and methods for generating immunotolerant responses in a subject. Specifically, the invention relates to a composition comprising a sulfated polysaccharide and a bioactive polypeptide for generating an immunotolerant response.

To provide active-ingredient-containing particles having higher absorption of the active ingredient into a body. Particles including a first fraction containing an active ingredient and a second fraction containing a surfactant, wherein the aggregability index X of the particles represented by formula (1) is 30 or less. Formula (1): X = (S1/Sr1)/(SO/Sr0) [In formula (1): S1 represents the scattering intensity when the scattering vector q in a scattering profile obtained by small-angle X-ray scattering in the particles is 0.2 [nm-1]; Sr1 represents the maximum value of the scattering intensity in the scattering profile obtained by small-angle X-ray scattering in the particles; S0 represents the scattering intensity when the scattering vector q in a scattering profile obtained by small-angle X-ray scattering in the surfactant is 0.2 [nm-1]; and Sr0 represents the maximum value of the scattering intensity in the scattering profile obtained by small-angle X-ray scattering in the surfactant.]

The present invention relates to viral or cellular membrane coated nanostructures. Nanostructure networks, nanoscaffolds and articles of manufacture comprising the nanostructure, and uses thereof, are also provided. The present invention also relates to methods for anchoring, attaching and/or growing a target cell. Target cells, constituent(s) of the target cells, target substances made by the target cells or culture medium of the target cells prepared by the present methods, and uses thereof, are also provided.

A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

The disclosure encompasses resurfaced cell-penetrating nanobodies and their methods of use. The resurfacing of nanobodies with positively-charged amino acids facilitates their penetration into a cell and allows targeting of a specific intracellular protein.

The present disclosure is directed to protocells or nanopartic!es, which are optionally coated with a lipid biiayer, which can be used for targeting bone tissue for the delivery of bioactive agents useful in the treatment and/or diagnosis of bone cancer, often metastatic bone cancer which often occurs secondary to a primary cancer such as prostate cancer, breast cancer, lung cancer and ovarian cancer, among numerous others. These protocells or nanopartic!es target bone cancer especially metastatic bone cancer with bioactive agents including anticancer agents and/or diagnostic agents for purposes of treating, diagnosing and/or monitoring the therapy of the bone cancer. Osteotropic protocells or nanopartic!es, pharmaceutical compositions comprising a population of osteotropic protocells or nanoparticles and methods of diagnosing, treating and/or monitoring therapy of bone cancer are representative aspects.

Described are nanoparticle complexes comprising paclitaxel, albumin and anti-CD52 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses CD52.

Described are nanoparticle complexes comprising paclitaxel, albumin and anti-HER2 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses HER2.

Protein polymer-gold nanoparticles, compositions comprising protein polymer-gold nanoparticles, and uses of protein polymer-gold nanoparticles. A protein polymer-gold nanoparticle comprises a gold core and a plurality of protein polymer molecules coordinated to the gold core via a poly-histidine tag present on each protein polymer molecule. A protein polymer molecule comprises one or more elastin-like polypeptide domain and a coiled-coil region of Cartilage Oligomeric Matrix Protein domain or a variant thereof. For example, the protein polymer-gold nanoparticles can be used in methods of small molecule delivery to an individual.

The present invention provides a method of treating a condition affecting a tooth or periodontium in a subject, comprising administering to the subject's tooth or periodontium a composition comprising biocompatible magnetic, magnetizable, or magnetically responsive agents; and applying an external magnetic field, wherein the magnetic, magnetizable, or magnetically responsive agents migrate to a desired location in response to the externally applied magnetic field, thereby treating a condition affecting the tooth or periodontium in the subject.

A therapeutic nanoparticle comprising: at least one oncologic drug; and taurolidine, whereby to provide the simultaneous delivery of the at least one oncologic drug and taurolidine, thereby harnessing the synergistic effect of taurolidine on the at least one oncologic drug.

[wherein, each symbol is as defined in the present description] or a salt thereof.

Described are nanoparticle complexes comprising paclitaxel, albumin and anti-HER2 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses VEGF.

Antimicrobial compounds are provided comprising: (i) a nucleic acid nanostructure; and (ii) a plurality of lipid molecules; wherein the plurality of lipid molecules are linked to the nucleic acid nanostructure. Compositions are provided with antimicrobial and antibiotic activity that comprise the described compounds. The compositions and compounds are selectively biocidal to microbes, especially bacteria, and not to eukaryotic cells.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

Provided are core-shell particles which are kept stable in a solvent such as water for a long period. Each core-shell particle includes a core which contains a hydrophobic polymer having an anionic group and a shell which contains calcium phosphate. At least one of calcium atoms contained in calcium phosphate is chemically bonded to a functional group derived from the anionic group. In a method of manufacturing core-shell particles each core-shell particle includes a core which contains a hydrophobic polymer and a shell which contains calcium phosphate, the method includes the steps of: mixing a water-soluble organic solution which contains a hydrophobic polymer having an anionic group with a solution which contains calcium ion so as to obtain a first mixed solution; mixing the first mixed solution with a solution which contains phosphate ions so as to obtain a second mixed solution; and stirring the second mixed solution.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

The present invention provides capsules having a shell of material that comprises an assembly of a protein, and the capsule is optionally provided with a network of material within the shell that is an assembly of the protein. The assembly of the protein is obtained or obtainable by the aggregation of the protein, optionally together with another protein. The assembly is a non-covalent assembly of a protein.

This invention provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Disclosed are targeted sub-50 nanometer nanoparticles suitable for delivering bioactive agents of interest, and related compositions, methods, and systems, which improve the manufacturing, stability, efficacy and other aspects of therapeutic nanoparticles.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

A system for "smart" delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through an injectable nano-network consisting of oppositely-charged dextran nanoparticles encapsulating insulin and glucose-specific enzymes forming a gel-like 3D scaffold. As demonstrated by the examples, the system effectively dissociates to release insulin in a hyperglycemic condition, where the catalytic conversion of glucose into gluconic acid and the subsequent degradation of polymeric matrix are facilitated. This formulation design provides a delivery strategy for both self-regulated and long-term diabetes management.